ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Grifols to acquire antiaging plasma start-up Alkahest for $146 million

by Ryan Cross
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

The Spanish blood plasma company Grifols will buy the antiaging plasma protein start-up Alkahest for $146 million. Grifols acquired a 45% stake in the firm in 2015. Alkahest was founded by Stanford University neuroscientist Tony Wyss-Coray in 2014 and is based on the discovery that the blood of young rodents improved the health and cognition of old rodents. The firm is seeking differences between young and old plasma that may influence aging. It has small-molecule and protein drug candidates in clinical trials for Alzheimer’s disease, Parkinson’s disease, and other conditions.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment